Repros Therapeutics (RPRX) Misses Q2 EPS by 6c

Repros Therapeutics (NASDAQ: RPRX) reported Q2 EPS of ($0.32), $0.06 worse than the analyst estimate of ($0.26).

The Company had cash and cash equivalents of approximately $32.2 million as of June 30, 2015 as compared to $46.6 million as of December 31, 2014. Net cash of approximately $14.6 million and $15.3 million was used in operating activities during the six month periods ended June 30, 2015 and 2014, respectively. The major use of cash for operating activities for the six month period ended June 30, 2015 was to fund our clinical development programs and associated administrative costs. No cash was used in investing activities during the six month period ended June 30, 2015. Cash provided by financing activities during the six month period ended June 30, 2015 was approximately $102,000 due to the receipt of that amount from a former 10% shareholder of the Company in accordance with Section 16(a) under the Securities Exchange Act of 1934, as amended.

For earnings history and earnings-related data on Repros Therapeutics (RPRX) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Acme United (ACU) Misses Q1 EPS by 20c
• Senesco Technologies, Inc. (SNT) Reports Q1 EPS of $0.02